Pluristem Therapeutics Inc. (PSTI) - 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated June 2, 2021, reports the results of the 2021 Annual Meeting of Stockholders held on June 1, 2021. Pluristem Therapeutics Inc. is a Nevada corporation with principal executive offices in Haifa, Israel, and its common stock trades on The Nasdaq Global Market under the symbol PSTI.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results and does not contain financial performance data.
Material Changes and Voting Results
The filing details the final voting results for three proposals at the Annual Meeting:
- Proposal 1 (Election of Directors): All seven nominees were elected. Zami Aberman, Maital Shemesh-Rasmussen, Rami Levi, and Yaky Yanay received overwhelming support (over 95% "For" votes). Mark Germain and Doron Shorrer received approximately 57% "For" votes, while Moria Kwiat received approximately 59% "For" votes. Significant broker non-votes (approx. 5.2 million) were recorded for all director nominees.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of Kesselman & Kesselman, Certified Public Accountants (Isr.), as the independent registered public accounting firm for the fiscal year ending June 30, 2021. The proposal passed with approximately 98.8% "For" votes.
- Proposal 3 (Executive Compensation): The nonbinding advisory vote on executive compensation passed with approximately 88.9% "For" votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to contextualize the voting percentages and broker non-vote counts.
- Confirm the tenure and background of directors Mark Germain and Doron Shorrer, who received lower support compared to other nominees.
- Review the company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial metrics.
- Check subsequent filings for any changes in the Board composition or auditor status following this meeting.